Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG.

J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.

2.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA, Jhee S, Kleijn HJ, Kuvelkar R, Li W, Mattson BA, Mei H, Palcza J, Scott JD, Tanen M, Troyer MD, Tseng JL, Stone JA, Parker EM, Forman MS.

Sci Transl Med. 2016 Nov 2;8(363):363ra150.

PMID:
27807285
3.

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.

Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L, Olsson T, Ye N, Rosen L, Russell M, Maltby J, Eketjäll S, Kugler AR.

J Alzheimers Dis. 2017;55(3):1039-1053.

PMID:
27767991
4.

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.

Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP.

Mol Psychiatry. 2016 Oct;21(10):1483-4. doi: 10.1038/mp.2016.140. Epub 2016 Aug 16. No abstract available.

5.

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.

Hofmann C, Pizzagalli F, Boetsch C, Alberati D, Ereshefsky L, Jhee S, Patat A, Boutouyrie-Dumont B, Martin-Facklam M.

Psychopharmacology (Berl). 2016 Jul;233(13):2429-39. doi: 10.1007/s00213-016-4317-7. Epub 2016 May 14.

PMID:
27178435
6.

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.

Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP.

Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. Epub 2015 Dec 8. Erratum in: Mol Psychiatry. 2016 Oct;21(10):1483-4.

7.

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.

May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martényi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ.

J Neurosci. 2015 Jan 21;35(3):1199-210. doi: 10.1523/JNEUROSCI.4129-14.2015.

8.

Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.

Llorca PM, Lançon C, Brignone M, Rive B, Salah S, Ereshefsky L, Francois C.

Curr Med Res Opin. 2014 Dec;30(12):2589-606. doi: 10.1185/03007995.2014.969566. Epub 2014 Oct 10.

PMID:
25249164
9.

Lurasidone drug-drug interaction studies: a comprehensive review.

Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A.

Drug Metabol Drug Interact. 2014;29(3):191-202. doi: 10.1515/dmdi-2014-0005. Review.

PMID:
24825095
10.

Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.

English BA, Thomas K, Johnstone J, Bazih A, Gertsik L, Ereshefsky L.

Biomark Med. 2014;8(1):29-49. doi: 10.2217/bmm.13.135. Review. Erratum in: Biomark Med. 2014 Feb;8(2):309-10.

PMID:
24325223
11.

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.

Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A.

Hum Psychopharmacol. 2013 Sep;28(5):495-505. doi: 10.1002/hup.2338.

PMID:
24014143
12.

Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384.

Katz DA, Liu W, Locke C, Jacobson P, Barnes DM, Basu R, An G, Rieser MJ, Daszkowski D, Groves F, Heneghan G, Shah A, Gevorkyan H, Jhee SS, Ereshefsky L, Marek GJ.

Transl Psychiatry. 2013 Aug 27;3:e295. doi: 10.1038/tp.2013.67.

13.

Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects.

Liang E, Garzone P, Cedarbaum JM, Koller M, Tran T, Xu V, Ross B, Jhee SS, Ereshefsky L, Pastrak A, Abushakra S.

Clin Pharmacol Drug Dev. 2013 Apr;2(2):186-94. doi: 10.1002/cpdd.14. Epub 2013 Mar 16.

PMID:
27121673
14.

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial.

Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, Gertsik L, Johnstone J, Lee A, Pande Y, Ruigt G, Ereshefsky L.

J Psychopharmacol. 2012 Dec;26(12):1525-39. doi: 10.1177/0269881112458728. Epub 2012 Sep 6.

PMID:
22954616
15.

Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.

Nations KR, Bursi R, Dogterom P, Ereshefsky L, Gertsik L, Mant T, Schipper J.

Drugs R D. 2012 Sep 1;12(3):127-39. doi: 10.2165/11634360-000000000-00000.

16.

Clinically significant psychotropic drug-drug interactions in the primary care setting.

English BA, Dortch M, Ereshefsky L, Jhee S.

Curr Psychiatry Rep. 2012 Aug;14(4):376-90. doi: 10.1007/s11920-012-0284-9.

17.

Application of external review for subject selection in a schizophrenia trial.

Targum SD, Little JA, Lopez E, Demartinis N, Rapaport M, Ereshefsky L.

J Clin Psychopharmacol. 2012 Apr;32(2):825-6. doi: 10.1097/JCP.0b013e318248da90. No abstract available.

PMID:
22388170
18.

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.

J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.

19.

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels.

Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, Waring JF.

Alzheimers Dement. 2012 Jul;8(4):295-303. doi: 10.1016/j.jalz.2011.05.900. Epub 2011 Nov 2.

PMID:
22047633
20.

The 6-month persistence on SSRIs and associated economic burden.

Ereshefsky L, Saragoussi D, Despiégel N, Hansen K, François C, Maman K.

J Med Econ. 2010;13(3):527-36. doi: 10.3111/13696998.2010.511050.

PMID:
20701432
21.

Cerebrospinal fluid beta-amyloid and dynabridging in Alzheimer's disease drug development.

Ereshefsky L, Jhee S, Yen M, Moran S, Pretorius S, Adams J.

Biomark Med. 2009 Dec;3(6):711-21. doi: 10.2217/bmm.09.39.

PMID:
20477709
22.

Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan.

Ereshefsky L.

CNS Spectr. 2009 Aug;14(8 Suppl Q and A Forum):1-8.

PMID:
20085108
23.

Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study.

Scharf M, Rogowski R, Hull S, Cohn M, Mayleben D, Feldman N, Ereshefsky L, Lankford A, Roth T.

J Clin Psychiatry. 2008 Oct;69(10):1557-64. Epub 2008 Oct 7.

PMID:
19192438
24.

What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dubé S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A.

Schizophr Bull. 2010 May;36(3):504-9. doi: 10.1093/schbul/sbn110. Epub 2008 Aug 22.

25.

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3687-93. doi: 10.1128/AAC.00327-08. Epub 2008 Aug 1.

26.

The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.

Velligan DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J, Ereshefsky L, Lam YW, Castillo D, Miller AL.

Schizophr Bull. 2008 May;34(3):483-93. Epub 2007 Oct 10.

27.

Relationships among subjective and objective measures of adherence to oral antipsychotic medications.

Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW, Ereshefsky L, Miller AL.

Psychiatr Serv. 2007 Sep;58(9):1187-92.

PMID:
17766564
28.

The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.

Derby MA, Zhang L, Chappell JC, Gonzales CR, Callaghan JT, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Mitchell MI.

J Cardiovasc Pharmacol. 2007 Jun;49(6):384-93.

PMID:
17577103
29.

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

Lefèvre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, Maton S, Ereshefsky L, Pommier F, Schmidli H, Appel-Dingemanse S.

Clin Pharmacol Ther. 2008 Jan;83(1):106-14. Epub 2007 May 23.

PMID:
17522596
30.

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, Francis JL, Desaiah D, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Derby M.

J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53.

PMID:
17414226
31.

Defining and assessing adherence to oral antipsychotics: a review of the literature.

Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL.

Schizophr Bull. 2006 Oct;32(4):724-42. Epub 2006 May 17. Review.

32.

Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects.

Jhee SS, Chappell AS, Zarotsky V, Moran SV, Rosenthal M, Kim E, Chalon S, Toublanc N, Brandt J, Coutant DE, Ereshefsky L.

J Clin Pharmacol. 2006 Apr;46(4):424-32.

PMID:
16554450
33.

Antidepressant drug-drug interaction profile update.

Ereshefsky L, Jhee S, Grothe D.

Drugs R D. 2005;6(6):323-36. Review.

PMID:
16274257
35.

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.

Miller A, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B.

J Clin Psychiatry. 2004 Apr;65(4):500-8. Review.

PMID:
15119912
36.

Clinical guidelines: Dosing and switching strategies for long-acting risperidone.

Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS.

J Clin Psychiatry. 2003;64 Suppl 16:41-6. No abstract available.

37.
38.

Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.

Lam YW, Alfaro CL, Ereshefsky L, Miller M.

J Clin Pharmacol. 2003 Nov;43(11):1274-82.

PMID:
14551182
39.

Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

Velligan DI, Lam F, Ereshefsky L, Miller AL.

Psychiatr Serv. 2003 May;54(5):665-7. No abstract available.

PMID:
12719495
40.
41.

The Texas Medication Algorithm Project for major depression.

Ereshefsky L.

Manag Care. 2001 Aug;10(8 Suppl):16-7; discussion 18-22. No abstract available.

42.

Antidepressant drug interaction considerations.

Ereshefsky L.

Manag Care. 2001 Aug;10(8 Suppl):10-3; discussion 18-22. No abstract available.

43.

Comparison of the bioequivalence of generic versus branded clozapine.

Ereshefsky L, Glazer WM.

J Clin Psychiatry. 2001;62 Suppl 5:25-7. No abstract available.

PMID:
11305845
44.

Branded versus generic clozapine: bioavailability comparison and interchangeability issues.

Lam YW, Ereshefsky L, Toney GB, Gonzales C.

J Clin Psychiatry. 2001;62 Suppl 5:18-22; discussion 23-4.

45.

Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.

Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM.

J Clin Pharmacol. 2001 Apr;41(4):443-51.

PMID:
11304901
46.
47.

Sleep disorders: assisting patients to a good night's sleep.

Toney G, Ereshefsky L.

J Am Pharm Assoc (Wash). 2000 Sep-Oct;40(5 Suppl 1):S46-7.

PMID:
11029866
48.
49.

All guidelines are not the same.

Ereshefsky L.

Am J Health Syst Pharm. 1999 Sep 15;56(18):1829. No abstract available.

PMID:
10511231
50.

Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.

Ereshefsky L.

J Clin Psychiatry. 1999;60 Suppl 10:20-30. Review.

Supplemental Content

Loading ...
Support Center